Jin Dong-Cai, Zhao Li
The First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, China.
Central Laboratory, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Feb;28(1):343-349. doi: 10.19746/j.cnki.issn.1009-2137.2020.01.058.
Abstract Although the majority of patients with Hodgkin's lymphoma (HL) can be cured with upfront treatment, but a fraction of patients with advanced disease will experience refractory or recurrence leading to poor prognosis. How to treat these patients is the focus of current research. High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (HDCT/auto-HSCT) is the standard salvage approach for patients with HL who have relapsed/refractory disease after frontline chemotherapy. In recent years, salvage therapy incorporating newer drugs, such as targeted drugs Brentuximab vedotin (BV), checkpoint inhibitors Nivolumab and Pembrolizumab have shown some efficacy in early clinical trials. In addition, Ibrutinib, Everolimus and other drugs have also shown a promising perspective. In this review, the advances in the therapy strategies for relapsed/refractory HL are discussed and summarized.
尽管大多数霍奇金淋巴瘤（HL）患者可通过初始治疗治愈，但一部分晚期患者会出现难治或复发，导致预后不良。如何治疗这些患者是当前研究的重点。大剂量化疗联合自体造血干细胞移植（HDCT/auto-HSCT）是一线化疗后复发/难治性HL患者的标准挽救治疗方法。近年来，包含新型药物的挽救治疗，如靶向药物维布妥昔单抗（BV）、检查点抑制剂纳武利尤单抗和帕博利珠单抗在早期临床试验中已显示出一定疗效。此外，伊布替尼、依维莫司等药物也显示出了有前景的前景。在本综述中，对复发/难治性HL治疗策略的进展进行了讨论和总结。
